Respiratory Disease Vaccine Market Analysis 2024-2033 : Forecast Market Size, Top Segments And Largest Region | Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC

"The respiratory disease vaccine market size has grown steadily in recent years. It will grow from $68.4 billion in 2023 to $69.99 billion in 2024 at a compound annual growth rate (CAGR) of 2.3%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, growing demand for effective and more tolerable vaccines.

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $76.18 billion in 2028 at a compound annual growth rate (CAGR) of 2.1%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, investments in vaccine, pandemic preparedness. Major trends in the forecast period include innovative vaccines, collaborative research, advancement in vaccine development, drug approval.

Market Overview -
Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

The Rising Incidence Of Tuberculosis Drives Growth In The Respiratory Disease Vaccine Market
The increasing incidence of tuberculosis is expected to propel the growth of the respiratory disease vaccine market going forward. Tuberculosis (TB) is a type of respiratory disease caused by the bacterium Mycobacterium tuberculosis, which primarily affects the lungs and potentially impacts other organs and systems in the body, leading to various complications. The increasing incidence of tuberculosis can catalyze efforts to develop and distribute respiratory disease vaccines to reduce the spread of tuberculosis. For instance, in October 2022, according to the Global Tuberculosis Report published by the World Health Organization, a Switzerland-based global health agency, the global incidence of tuberculosis (TB) was estimated at 10.6 million cases, with a rate of 134 cases per 100,000 population in 2021, an increase of 4.5% from 10.1 million in 2020. Therefore, the increasing incidence of tuberculosis will drive the respiratory disease vaccine market.

Competitive Landscape -
Major players in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Major Players Strive For An Improved Solution Enhancing Efficacy And Prevention
Major companies operating in the respiratory disease vaccine market are concentrating on creating innovative products to enhance their efficacy and provide improved solutions for preventing and treating respiratory disease infections. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company, received Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties and it has been clinically proven to be safe and productive.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Key Segments -
The respiratory disease vaccine market covered in this report is segmented -
1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
2) By Infection: COVID-19; Influenza; Respiratory Syncytial Virus (RSV); Pneumonia; Other Infections
3) By Age: Infant; Adolescent; Adult
4) By End-User: Clinic; Hospital; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.